Sera Prognostics (SERA) Income from Non-Controlling Interests (2021 - 2026)
Sera Prognostics (SERA) posted Income from Non-Controlling Interests of -$246000.0 for Q1 2026, down 4000.0% on a QoQ basis from -$6000.0 in Q4 2025, and down 1637.5% year-over-year from $16000.0 in Q1 2025.
Sera Prognostics (SERA) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Sera Prognostics' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$246000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 1637.5% year-over-year to -$246000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60000.0 (down 123.35% YoY) and the FY2025 annual result came in at $202000.0, up 169.33% from the prior year.
- Income from Non-Controlling Interests was -$246000.0 for Q1 2026 at Sera Prognostics, down from -$6000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $599000.0 in Q4 2023 and bottomed at -$473000.0 in Q1 2022.
- A 5-year average of $11705.9 and a median of -$6000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests soared 767.24% — and 2026, when it plunged 1637.5%.
- Sera Prognostics' Income from Non-Controlling Interests stood at $188000.0 in 2022, then soared by 218.62% to $599000.0 in 2023, then plunged by 138.73% to -$232000.0 in 2024, then jumped by 97.41% to -$6000.0 in 2025, then plunged by 4000.0% to -$246000.0 in 2026.
- Business Quant data shows SERA's Income from Non-Controlling Interests at -$246000.0 in Q1 2026, -$6000.0 in Q4 2025, and $123000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.01 Bn | 175.72 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.76 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.90 Bn | 99.68 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 47.96 Bn | 44.29 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | 22.00 Mn |
| 7 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.44 Bn | 22.31 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Sera Prognostics | 102.28 Mn | 102.28 Mn | -28,000.00 | -246,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -246,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | -232,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | 599,000.00 |
| Sep 30, 2023 | 58,000.00 |
| Jun 30, 2023 | -215,000.00 |
| Mar 31, 2023 | 524,000.00 |
| Dec 31, 2022 | 188,000.00 |
| Sep 30, 2022 | -351,000.00 |
| Jun 30, 2022 | -162,000.00 |
| Mar 31, 2022 | -473,000.00 |
| Dec 31, 2021 | -158,000.00 |
| Sep 30, 2021 | -25,000.00 |